Race Oncology Ltd (ASX:RAC, OTC:RAONF) will present at the Gold Coast Investment Showcase on June 25–26, 2025 and hold an investor briefing in Brisbane on June 27. Chief executive officer Dr Daniel Tillett and executive chairman Dr Pete Smith will deliver company updates and engage directly with shareholders and prospective investors. These engagements come as the company continues clinical development of its lead asset, bisantrene (RC220), and pursues partnerships to broaden patient access.
Gold Coast Investment Showcase
Race will participate in the upcoming Gold Coast Investment Showcase held at the JW Marriott Gold Coast Resort & Spa, with Tillett scheduled to present at 10:30 am on Thursday, June 26. He will also be available across both days at the Race booth to meet with attendees and discuss the company’s latest developments, including progress on its RC220 formulation and clinical programs.
Additional information and registration details are available via the event website: www.goldcoastinvestmentshowcase.com.au
Brisbane investor briefing
Race will host an in-person investor briefing in Brisbane on Friday, June 27, 2025, featuring a presentation byl Tillett and Smith. The session will include a Q&A segment and a light morning tea.
Event details
- Date: Friday, 27 June 2025
- Time: 10:15 am for a 10:30 am start; concluding at 12:00 pm
- Venue: Workspace 365, Level 4, 260 Queen Street, Brisbane, Queensland
- RSVP: By Monday, 16 June 2025 to anna.cvijetic@irdepartment.com.au